SI-BONE, Inc. (NASDAQ:SIBN) Receives $23.00 Consensus Target Price from Analysts

Shares of SI-BONE, Inc. (NASDAQ:SIBN) have earned an average recommendation of “Buy” from the six research firms that are currently covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have covered the stock in the last year is $23.00.

A number of equities research analysts have recently issued reports on SIBN shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 target price on shares of SI-BONE in a report on Wednesday, November 20th. Truist Financial upped their price objective on SI-BONE from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th.

SI-BONE Stock Performance

NASDAQ SIBN opened at $13.25 on Wednesday. The firm has a market capitalization of $555.68 million, a P/E ratio of -14.40 and a beta of 1.20. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22. The firm’s fifty day moving average price is $13.42 and its two-hundred day moving average price is $14.09. SI-BONE has a 1 year low of $11.70 and a 1 year high of $21.70.

Insider Activity at SI-BONE

In related news, insider Anthony J. Recupero sold 3,305 shares of the business’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $13.58, for a total value of $44,881.90. Following the completion of the sale, the insider now directly owns 233,412 shares in the company, valued at $3,169,734.96. The trade was a 1.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Anshul Maheshwari sold 2,439 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $12.68, for a total value of $30,926.52. Following the completion of the transaction, the chief financial officer now directly owns 194,623 shares in the company, valued at approximately $2,467,819.64. This represents a 1.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 21,679 shares of company stock worth $276,439. Insiders own 3.90% of the company’s stock.

Institutional Trading of SI-BONE

Hedge funds and other institutional investors have recently bought and sold shares of the business. Millrace Asset Group Inc. acquired a new position in SI-BONE in the 3rd quarter valued at $1,056,000. Champlain Investment Partners LLC increased its position in shares of SI-BONE by 14.7% in the third quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company’s stock worth $39,145,000 after purchasing an additional 358,821 shares during the period. Impax Asset Management Group plc raised its stake in SI-BONE by 41.3% in the third quarter. Impax Asset Management Group plc now owns 758,521 shares of the company’s stock valued at $10,604,000 after purchasing an additional 221,604 shares in the last quarter. American Century Companies Inc. lifted its position in SI-BONE by 22.8% during the second quarter. American Century Companies Inc. now owns 1,986,476 shares of the company’s stock worth $25,685,000 after purchasing an additional 368,637 shares during the period. Finally, Divisadero Street Capital Management LP bought a new stake in SI-BONE during the second quarter worth about $1,552,000. Institutional investors and hedge funds own 98.11% of the company’s stock.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.